Complete financial analysis of Adamas Pharmaceuticals, Inc. (ADMS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Adamas Pharmaceuticals, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Hwang Chang General Contractor Co., Ltd (2543.TW) Income Statement Analysis – Financial Results
- 888 Holdings plc (888.L) Income Statement Analysis – Financial Results
- Santos Limited (SSLZY) Income Statement Analysis – Financial Results
- Braveheart Resources Inc. (BHT.V) Income Statement Analysis – Financial Results
- Gores Technology Partners II, Inc. (GTPBU) Income Statement Analysis – Financial Results
Adamas Pharmaceuticals, Inc. (ADMS)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: http://www.adamaspharma.com
About Adamas Pharmaceuticals, Inc.
Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. It is also developing ADS-5102 that is in Phase III clinical study to treat walking impairment in patients with multiple sclerosis and other indications; and ADS-4101, which has completed two Phase I studies for treating partial onset seizures in patients with epilepsy. In addition, the company offers Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 74.46M | 54.64M | 34.05M | 571.00K | 572.00K | 1.92M | 55.85M | 71.10M | 37.47M |
| Cost of Revenue | 2.04M | 2.47M | 633.00K | 17.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 72.42M | 52.17M | 33.41M | 554.00K | 572.00K | 1.92M | 55.85M | 71.10M | 37.47M |
| Gross Profit Ratio | 97.26% | 95.48% | 98.14% | 97.02% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 9.75M | 30.03M | 39.30M | 27.17M | 31.23M | 35.90M | 21.86M | 7.41M | 9.19M |
| General & Administrative | 106.84M | 114.37M | 109.14M | 61.31M | 30.33M | 23.46M | 15.47M | 6.67M | 8.33M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 106.84M | 114.37M | 109.14M | 61.31M | 30.33M | 23.46M | 15.47M | 6.67M | 8.33M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 116.59M | 144.40M | 148.44M | 88.48M | 61.56M | 59.35M | 37.33M | 14.08M | 17.52M |
| Cost & Expenses | 118.63M | 146.87M | 149.07M | 88.50M | 61.56M | 59.35M | 37.33M | 14.08M | 17.52M |
| Interest Income | 748.00K | 2.09M | 3.12M | 1.35M | 811.00K | 363.00K | -917.00K | -4.82M | -1.91M |
| Interest Expense | 13.24M | 15.04M | 19.09M | 4.65M | 0.00 | 0.00 | 0.00 | 4.91M | 0.00 |
| Depreciation & Amortization | 851.00K | 1.21M | 1.46M | 1.19M | 808.00K | 435.00K | 155.00K | 66.00K | 41.00K |
| EBITDA | -43.31M | -88.93M | -110.45M | -85.38M | -59.37M | -56.64M | 17.75M | 57.08M | 18.08M |
| EBITDA Ratio | -58.17% | -162.76% | -324.41% | -14,952.89% | -10,378.50% | -2,956.11% | 31.79% | 80.29% | 48.24% |
| Operating Income | -44.16M | -92.24M | -115.02M | -87.93M | -60.98M | -57.44M | 18.51M | 57.02M | 19.95M |
| Operating Income Ratio | -59.31% | -168.81% | -337.84% | -15,398.60% | -10,661.54% | -2,997.76% | 33.15% | 80.20% | 53.24% |
| Total Other Income/Expenses | -13.24M | -12.95M | -15.98M | -3.29M | 811.00K | 363.00K | -917.00K | -4.91M | -1.91M |
| Income Before Tax | -57.40M | -105.19M | -131.00M | -91.22M | -60.17M | -57.07M | 17.60M | 52.11M | 18.04M |
| Income Before Tax Ratio | -77.09% | -192.52% | -384.77% | -15,975.48% | -10,519.76% | -2,978.81% | 31.51% | 73.30% | 48.13% |
| Income Tax Expense | 0.00 | 2.09M | 3.12M | -1.73M | -115.00K | -5.27M | 7.37M | 1.19M | 300.00K |
| Net Income | -57.40M | -105.19M | -131.00M | -89.49M | -60.06M | -51.80M | 10.22M | 50.92M | 17.74M |
| Net Income Ratio | -77.09% | -192.52% | -384.77% | -15,672.50% | -10,499.65% | -2,703.65% | 18.31% | 71.62% | 47.33% |
| EPS | -1.63 | -3.80 | -4.87 | -3.97 | -2.77 | -2.86 | 0.69 | 3.80 | 1.87 |
| EPS Diluted | -1.63 | -3.80 | -4.87 | -3.97 | -2.77 | -2.86 | 0.60 | 3.22 | 1.50 |
| Weighted Avg Shares Out | 35.17M | 27.68M | 26.89M | 22.56M | 21.71M | 18.11M | 14.84M | 13.41M | 9.51M |
| Weighted Avg Shares Out (Dil) | 35.17M | 27.68M | 26.89M | 22.56M | 21.71M | 18.11M | 17.11M | 15.79M | 11.81M |
Time Sensitive - Reminder from Levi & Korsinsky, LLP to File Claim for Share of Adamas Pharmaceuticals, Inc. (ADMS) Settlement Fund Before Deadline
NEW YORK, NY / ACCESSWIRE / June 27, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS). The settlement provides for a fund of $4,650,000...
$4,650,000 Recovery from Adamas Pharmaceuticals, Inc. (ADMS). L&K, LLP Reminds Shareholders to File a Claim Before Deadline
NEW YORK, NY / ACCESSWIRE / June 25, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS). The settlement provides for a fund of $4,650,000...
Deadline Approaching for Receiving Share of Adamas Pharmaceuticals, Inc. (ADMS) Recovery - Contact Levi & Korsinsky, LLP for Further Details
NEW YORK, NY / ACCESSWIRE / June 20, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS). The settlement provides for a fund of...
Deadline Approaching for Receiving Share of Adamas Pharmaceuticals, Inc. (ADMS) Recovery - Contact Levi & Korsinsky, LLP for Further Details
NEW YORK, NY / ACCESSWIRE / June 18, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS). The settlement provides for a fund of...
Levi & Korsinsky, LLP Announces $4,650,000 Recovery for Adamas Pharmaceuticals, Inc. (ADMS). File Your Claim Before Deadline
NEW YORK, NY / ACCESSWIRE / June 11, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS). The settlement provides for a fund of...
Looming Deadline - Levi & Korsinsky Encourages Shareholders of Adamas Pharmaceuticals, Inc. (ADMS) to File a Share in Class Action Recovery
NEW YORK, NY / ACCESSWIRE / June 6, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS). The settlement provides for a fund of $4,650,000...
Looming Deadline - Levi & Korsinsky Encourages Shareholders of Adamas Pharmaceuticals, Inc. (ADMS) to File a Share in Class Action Recovery
NEW YORK, NY / ACCESSWIRE / June 4, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS). The settlement provides for a fund of $4,650,000...
Levi & Korsinsky, LLP Notifies Shareholders of Adamas Pharmaceuticals, Inc. (ADMS) an Upcoming Claims Deadline in a Class Action Settlement
NEW YORK, NY / ACCESSWIRE / May 30, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS). The settlement provides for a fund of $4,650,000...
Levi & Korsinsky, LLP Notifies Shareholders of Adamas Pharmaceuticals, Inc. (ADMS) an Upcoming Claims Deadline in a Class Action Settlement
NEW YORK, NY / ACCESSWIRE / May 16, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS). The settlement provides for a fund of $4,650,000...
Levi & Korsinsky, LLP Notifies Shareholders of Adamas Pharmaceuticals, Inc. (ADMS) an Upcoming Claims Deadline in a Class Action Settlement
NEW YORK, NY / ACCESSWIRE / May 14, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS). The settlement provides for a fund of...
Source: https://incomestatements.info
Category: Stock Reports